All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
TRANSLATE
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Roche, Sobi and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Incyte, and Lilly. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
ASH 2025 | Top abstracts: What’s hot in lymphoma and CLL?
To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.
Oral presentations: Saturday, December 6, 2025
| Abstract | Title | Speaker | Time (EST) |
| 55 | Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II study FIL_RI-CHOP | Alice Di Rocco | 09:30–09:45 |
| 58 | Results of the primary end-point of the LOC-R01: A randomized phase II study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) | Carole Soussain | 10:15–10:30 |
| 61 | Phase II frontline chemolight R-Pola-Glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma | Björn Chapuy | 09:30–09:45 |
| 62 | Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study | Jeff Sharman | 09:45–10:00 |
| 63 | Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3 | Umberto Vitolo | 10:00–10:15 |
| 65 | Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First results from Part 1 of the phase 3 Olympia-3 study | Jean-Marie Michot | 10:30–10:45 |
| 85 | Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study | Inhye Ahn | 09:30–09:45 |
| 86 | Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing phase 1a/b trial | Zulfa Omer | 09:45–10:00 |
| 88 | Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis) | Keshu Zhou | 10:15–10:30 |
| 151 | 3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma | Alex Herrera | 12:00–12:15 |
| 152 | Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma | Justin Ferdinandus | 12:15–12:30 |
| 155 | First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation | Swetha Thiruvengadam | 13:00–13:15 |
| 223 | Dexamethasone, rituximab and cyclophosphamide with bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström’s macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström’s Macroglobulinemia (ECWM) | Meletios Dimopoulos | 14:00–14:15 |
| 225 | High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study | Jorge Castillo | 14:30–14:45 |
| 226 | Pirtobrutinib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the phase 1/2 BRUIN study | Chan Cheah | 14:45–15:00 |
| 227 | Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma | Pier Luigi Zinzani | 15:00–15:15 |
| 228 | Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study | John M. Burke | 15:15–15:30 |
Oral presentations: Sunday, December 7, 2025
| Abstract | Title | Speaker | Time (EST) |
| 463 | Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 MITHIC-FL2 trial | Lorenzo Falchi | 09:30–09:45 |
| 464 | Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial | Reid Merryman | 09:45–10:00 |
| 465 | Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from EPCORE NHL-2 Arms 6 and 7 | Lori Leslie | 10:00–10:15 |
| 466 | Primary phase 3 results from the EPCORE FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma | Lorenzo Falchi | 10:15–10:30 |
| 467 | Three-year efficacy and longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients with third-line or later (3L+) follicular lymphoma (FL) from TRANSCEND FL | Sairah Ahmed | 10:30–10:45 |
| 468 | Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update | Stephen Schuster | 10:45–11:00 |
| 475 | Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma: topline efficacy and safety results from the randomized phase 3 DEB study | Wei Li Zhao | 09:30–09:45 |
| 476 | Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy results | Grzegorz Nowakowski | 09:45–10:00 |
| 477 | Primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma | Jason Westin | 10:00–10:15 |
| 568 | Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL) | Mahipal Suraneni | 12:45–13:00 |
| 569 | ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) Burkitt lymphoma (BL), substudy C | Suzanne Van Dorp | 13:00–13:15 |
| 662 | High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort | Marie José Kersten | 16:45–17:00 |
| 663 | Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1/2 study | Michael Wang | 17:00–17:15 |
| 664 | Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO) | Austin Kim | 17:15–17:30 |
| 665 | Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): Final update from the phase 1/2 BRUIN study | Michael Wang | 17:30–17:45 |
| 666 | Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: The WINDOW-3 clinical trial | Preetesh Jain | 17:45–18:00 |
| 668 | Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma | Sarah Larson | 16:45–17:00 |
| 669 | Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for relapsed/refractory large B-cell lymphoma: Primary analysis of the randomized, pivotal DALY 2-EU study | Peter Borchmann | 17:00–17:15 |
| 670 | Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results | Jason Westin | 17:15–17:30 |
| 671 | Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study | Dasom (Caroline) Lee | 17:30–17:45 |
| 679 | MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial | Surita Dalal | 16:30–16:45 |
| 680 | Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia | Nitin Jain | 16:45–17:00 |
| 681 | Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized phase II trial for treatment naïve CLL | Mahesh Swaminathan | 17:00–17:15 |
| 682 | Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial | Hyun Yong Jin | 17:15–17:30 |
| 683 | Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor | Jennifer Woyach | 17:30–17:45 |
| 684 | Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial | Romain Guieze | 17:45–18:00 |
Oral presentations: Monday, December 8, 2025
| Abstract | Title | Speaker | Time (EST) |
| 775 | Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma | Swami Iyer | 10:30–10:45 |
| 776 | Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study | Huiqiang Huang | 10:45–11:00 |
| 778 | Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) | Richard Miller | 11:15–11:30 |
| 780 | A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed/refractory peripheral T-cell lymphoma | Ting Xu | 11:45–12:00 |
| 793 | MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101 | Marc Hoffmann | 10:30–10:45 |
| 794 | Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL | Peter Hillmen | 10:45–11:00 |
| 795 | Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial | Carsten Niemann | 11:00–11:15 |
| 883 | Interim analysis of the phase II study of glofitamab, lenalidomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of Stage 1 of 2 enrollment. | Tycel Phillips | 14:45–15:00 |
| 884 | Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAVeRse study | Monique Menzies Wojtowicz | 15:00–15:15 |
| 885 | Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up | Michael Wang | 15:15–15:30 |
| 888 | Preliminary safety and efficacy of BOVen (zanubrutinib, obinutuzumab, and venetoclax) as frontline therapy for older patients with mantle cell lymphoma | Anita Kumar | 16:00–16:15 |
| 1004 | Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the Fondazione Italiana Linfomi (FIL). | Stefano Luminari | 16:45–17:00 |
| 1015 | Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial | Philip Thompson | 16:45–17:00 |
| 1017 | Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial | Arnon Kater | 16:30–16:45 |
Oral presentations: Tuesday, December 9, 2025
| Abstract | Title | Speaker | Time (EST) |
| LBA-3 | Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients | Wojciech Jurczak | 08:00–08:15 |
Posters
| Abstract | Title | Speaker | Time (EST) |
| 5519 | Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO | Jeremy Abramson | Monday, December 8, 18:00–20:00 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?
